Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RB1 | P06400 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456916 | 0.89 | HTR2A (0.51) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL223751 | 0.78 | ALDH1A1 (0.50) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL224482 | 0.72 | MEN1 (0.47) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL537823 | 0.71 | KDM4E (0.49) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL1825781 | 0.71 | HTR2A (0.46) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL620253 | 0.69 | TAAR1 (0.78) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL224289 | 0.69 | HTR2C (0.57) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL481360 | 0.68 | KDM4E (0.68) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL30160092 | 0.68 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL29936982 | 0.68 | KDM4E (0.68) | KDM4EALDH1A1SMN1; SMN2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-05-16 | — | — | US | disclosed |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | BIOND BIOLOGICS LTD. (IL) | 2024-05-09 | — | — | US | disclosed |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| US-20230201201-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-06-29 | — | — | US | disclosed |
| US-20230124527-A1 | NANOPARTICLES FOR CHEMIRESISTOR SENSORS | NANOSCENT LTD. (IL) | 2023-04-20 | — | — | US | disclosed |
| US-20230104413-A1 | NANOPARTICLES FOR CHEMIRESISTOR SENSORS | NANOSCENT LTD. (IL) | 2023-04-06 | — | — | US | disclosed |
| EP-4146633-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | Rambam Med-Tech Ltd. (IL) | 2023-03-15 | — | — | EP | disclosed |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| EP-4004127-A1 | COATING COMPOSITIONS WITH POLYSILOXANE-MODIFIED CARBON NANOPARTICLE | Valfre' di Bonzo, Roberto (CH) | 2022-06-01 | — | — | EP | disclosed |
| US-11307158-B1 | Nanoparticles for chemiresistor sensors | NANOSCENT LTD. (IL) | 2022-04-19 | — | — | US | disclosed |
| US-20090311237-A1 | Combination therapy using a soluble hyaluronidase and a bisphosphonate | HALOZYME THERAPEUTICS, INC. | 2009-12-17 | — | — | US | disclosed |
| WO-2009128918-A1 | COMBINATION THERAPY USING A SOLUBLE HYALURONIDASE AND A BISPHOSPHONATE | HALOZYME, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-7582794-B2 | Process for the preparation of substituted 2-(phenoxymethyl)benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| WO-2009009117-A2 | CHEMOENZYMATIC PROCESSES FOR PREPARATION OF LEVETIRACETAM | BIOVERDANT, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1699748-B1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7238835-B2 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| EP-1699748-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-09-13 | — | — | EP | disclosed |
| US-20050171205-A1 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| WO-2005061427-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201201-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | APOL1, APOB, LIPA | KDM4E 4686/4885ALDH1A1 1761/4885SMN1; SMN2 131/4885 |
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | CYP2B6, CYP1B1, CYP4B1 | KDM4E 1144/4885ALDH1A1 285/4885SMN1; SMN2 2822/4885 |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | LCAT, CD47, PHOSPHO1 | KDM4E 1481/4885ALDH1A1 2268/4885SMN1; SMN2 2306/4885 |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | ACTB, CHERP, EEA1 | KDM4E 4424/4885ALDH1A1 4745/4885SMN1; SMN2 1140/4885 |
| US-20050171205-A1 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | CYP2B6, CYP1B1, CYP4B1 | KDM4E 1144/4885ALDH1A1 285/4885SMN1; SMN2 2822/4885 |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | KDM4E 1561/4885ALDH1A1 1243/4885SMN1; SMN2 4673/4885 |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | IGF2BP1, IGF2BP2, IGF2BP3 | KDM4E 2805/4885ALDH1A1 3459/4885SMN1; SMN2 91/4885 |
| US-20090311237-A1 | Combination therapy using a soluble hyaluronidase and a bisphosphonate | HEXD, BPGM, HEXA | KDM4E 4542/4885ALDH1A1 1066/4885SMN1; SMN2 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.